Wolfe Research Lowered Blueprint Medicines Corporation (BPMC) from Outperform to Peer Perform

Wolfe Research downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Peer Perform from Outperform without a price objective.

Wolfe Research lowered Blueprint from Outperform to Peer Perform

A doctor examining a patient’s samples in a modern hospital setting.

This happened after Sanofi announced plans to buy the company for $9.1 billion in stock value and up to $9.5 billion in contingent value rights. According to the company, the transaction values Blueprint Medicines Corporation (NASDAQ:BPMC)’s stock at about $129 per share.

The firm has a healthy $900 million cash position that allows it to keep funding R&D and business ventures to spur long-term expansion. Its pipeline expansion and the scaling of important items like AYVAKIT are supported by this financial flexibility.

Since AYVAKIT was approved for indolent systemic mastocytosis, the prescriber base has tripled, showing solid uptake and a positive market response, with over 95% of patients reporting excellent satisfaction.

Blueprint Medicines Corporation (NASDAQ:BPMC) is a biopharmaceutical business. It is developing medications in the following areas of focus: hematology, oncology, inflammation, and allergy.

While we acknowledge the potential of BPMC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BPMC and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.